期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 71, 期 8, 页码 1889-1896出版社
SPRINGER
DOI: 10.1007/s00262-021-03121-0
关键词
Gallbladder cancer; PD-1; Lenvatinib; PD-L1 expression
资金
- International Science and Technology Cooperation Projects [2016YFE0107100]
- CAMS Clinical and Translational Medicine Research Funds [2019XK320006]
- CAMS Innovation Fund for Medical Science (CIFMS) [2017-I2M-4-003, 2018-I2M-3-001]
- Beijing Natural Science Foundation [L172055, 7192158]
- Fundamental Research Funds for the Central Universities [3332018032]
- CSCO-hengrui Cancer Research Fund [Y-HR20190239]
- National Ten-thousand Talent Program
Anti-PD-1 antibodies plus lenvatinib show effectiveness and tolerability in patients with advanced gallbladder cancer.
Background Anti-PD-1 antibodies plus lenvatinib therapeutic regimens have demonstrated a relatively high antitumor response in many solid cancers; however, the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer (GBC) has not been reported. Methods Advanced GBC patients who received anti-PD-1 antibodies plus lenvatinib were retrospectively screened. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), PD-L1 expression and safety were evaluated to identify efficacy biomarkers. Results A total of 31 GBC patients were included in this study. After a median follow-up of 8 months and 23 deaths were observed. The median PFS was 5.0 months (95% CI: 4.1-8.0 months), and the median OS was 11.3 months (95% CI: 7.5-20.9 months). Overall, the ORR was 32.3%, the DCR was 83.9%, and the CBR was 41.9%. Moreover, after treatment, 3 patients received conventional surgery, in which 1 patient achieved a pathological complete response. All patients (100%) experienced adverse events (AEs), and 58.1% of the patients experienced grade 3 AEs. The most commonly observed grade 3 AEs included fatigue (5/31, 16.1%), decreased appetite (5/31, 16.1%), hypertension (4/31, 12.9%) and bilirubin elevation (4/31, 12.9%). Subgroup analysis revealed that positive PD-L1 expression maybe associate with a longer PFS. Conclusion Anti-PD-1 antibodies plus lenvatinib represent an effective and tolerable therapy for patients with advanced gallbladder cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据